Captrust Financial Advisors Cure Vac N.V. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$13.18 - $19.41 $13 - $19	-1 Reduced 1.96%	50 $1,000
Q2 2022 Aug 16, 2022	SELL	$13.18 - $19.41 $65 - $97	-5 Reduced 8.93%	51 $1,000
Q1 2022 May 16, 2022	SELL	$14.73 - $35.25 $1,399 - $3,348	-95 Reduced 62.91%	56 $1,000
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $168 - $241	-5 Reduced 3.21%	151 $5,000
Q3 2021 Nov 16, 2021	BUY	$49.26 - $74.5 $7,684 - $11,622	156 New	156 $9,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.